Verona Pharma (LON:VRP) has been assigned a consensus rating of “Buy” from the seven brokerages that are covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is GBX 116.20 ($1.58).
A number of equities analysts recently commented on VRP shares. N+1 Singer reaffirmed a “strong-buy” rating on shares of Verona Pharma in a report on Friday, March 2nd. Shore Capital started coverage on Verona Pharma in a report on Wednesday, April 11th. They issued a “buy” rating and a GBX 173 ($2.35) target price on the stock. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Verona Pharma in a report on Friday, April 6th.
Shares of LON VRP remained flat at $GBX 155 ($2.10) during midday trading on Wednesday. The stock had a trading volume of 370,973 shares, compared to its average volume of 49,797. Verona Pharma has a 12-month low of GBX 100 ($1.36) and a 12-month high of GBX 189 ($2.56).
Verona Pharma (LON:VRP) last released its quarterly earnings results on Tuesday, May 8th. The company reported GBX (14.50) (($0.20)) earnings per share for the quarter, beating the consensus estimate of GBX (23.70) (($0.32)) by GBX 9.20 ($0.12).
About Verona Pharma
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.